Synairgen Share Discussion Threads

[s120896] 09/5/2020 02:44

Happy weekend all.

Positive results from Hong Kong today using triple combo drugs (including interferon). Although trial wasn’t blinded still positive news.

eurekalert.org/pub_releases/2020-05/tl-pss050820.php

abcnews.go.com/Health/triple-combination-therapy-shows-promise-covid-19-patients/story?id=70580878

[phurley] 08/5/2020 22:23

Ok thanks for that. Have a good weekend all

[l0ngterm] 08/5/2020 21:03

I would just call all this the usual noise. It's a risk, it's a pump, etc. The market cap is slightly below where I would expect it to be for a small pharma, at this stage. Including the II selling it makes sense, so just normal behaviour and the market is telling us this is normal.

[coxypete] 08/5/2020 20:23

PHurley - wouldn't call it pump and dump - share price ultimately will be driven by results of clinical trials being run which are due out in June. Some of the fluctuation in share price are down to an earlier placement and also certain hot money coming in and out - as most know a real shift won't happen until trial results.

[phurley] 08/5/2020 20:17

Has this been a pump n dump?This was all over the press and the share price only fallen since then

[nobbygnome] 08/5/2020 20:05

>> dealer

But sadly, it's very unlikely to be the silver bullet which cures everyone. It will have a beneficial effect in a proportion of patients at best most likely. Still good enough to make lots of money though.....

[hazl] 08/5/2020 18:43

Nobby of course that is true.....but we are in markets and markets get driven by speculation!

[dealer55] 08/5/2020 18:38

No matter the cost of you can prove that covid can be fixed by your product the whole world can relax and return to normal. That’s literally Priceless.

[fatnacker] 08/5/2020 17:25

The trial is double blind, you cannot draw any conclusions from the additional trial extension what so ever for that very reason.

[paradise city] 08/5/2020 13:53

Small change against the gdp of the economy imo !

[nobbygnome] 08/5/2020 12:39

Until we get the results of the trials the appropriate word is pure speculation. Scientists are evidence driven so all that matters is the data. When you get the new evidence you amend your view appropriately or not as the case might be.

[141jaffa] 08/5/2020 12:34

Sorry, just an opinion for what it’s worth (I’m no expert at all !! )
Looking at all the recent info re: ACE2 etc (and SNG obviously know this back to front), timing seemed crucial with this drug. Ie earlier the better.
Hosp. didn’t look ideal to me in terms of the right candidates ( ie as stated, delays in getting CV tested / pt already been ill for some time), but did include bloods and sputum bio markers. I presume these are excluded in the more “remote” home trial ??
I wouldn’t be surprised to see much better results for the home trial.... hopefully "conclusive" !!.... fingers crossed . Glad theyre able to compare the two timings of intervention with 2 arms though to the trial now. IMO

Will the trial report as one ? I presumed so, as its just 2 arms of the same trial, but am I correct ??

[nobbygnome] 08/5/2020 11:50

'Wrong' is an unnecessarily emotive word. It may be true that the drug will be better used earlier in the course of the infection but the reality is no-one knows the answer to that question until we get the results of the trials. A hospital trial is way easier to set up which is why I suspect they went for that first and it makes complete sense to follow on as soon as was practically possible with a home trial.

All IMHO....

[nobbygnome] 08/5/2020 11:01

>> wetdream

The UK is a cr*p market from various points of view and I wouldn't get hung up on it. The rest of Europe, the US, Japan (and certain other parts of the Far East) and certain countries in the Middle East are what you want to focus on.

[141jaffa] 08/5/2020 10:37

RM was asked that question in the Q/A presentation posted yesterday. He side-stepped the cost since it was sensitive to AZN collaboration at the time in relation to COPD / asthma.He was able to say though that whilst not a cheap drug, it had to be seen in the wider context of the savings of hosp. admissions, and lives. If it had its market then, if effective (v) CV19 ( or the next one ?!), it's market must be assured almost whatever the cost now ?

[wetdream] 08/5/2020 10:06

I get the impression that RM doesn’t envisage the price of SNG001 being his company’s problem.
While UK drug prices are not directly controlled, Pharmaceutical company profits are regulated in the UK within the PPRS, so anyone acquiring Synairgen would be able to integrate them within the scheme.
Increasingly, NICE has a say over the cost of treatment (per patient per year), so companies would have to enter discussions with the DoH before the NHS would pay for the drug.
The more the focus moves to the community, imho the lower the price (since volume will increase). A lower price may also discourage competition.
So, imho, there’s a longer term strategy at play here.

[amaretto1] 08/5/2020 10:04

Will this one ?

[nobbygnome] 08/5/2020 09:49

>> afewbob

Yes in 28 years of working in Pharma, of all the projects I was involved in which was certainly in double figures, only one has so far reached the market. Admittedly that is now turning over £1.5 billion but nevertheless highlights the point about the cost of all the failed projects!

[fatnacker] 08/5/2020 09:27

To be fair it reduced the number of days on a ventilator and the patient didn't die.

[oohrogerpalmer] 08/5/2020 09:17

Didn't I read somewhere that this test showed that only in 31% of patients did it reduced the number of days needed on a ventilator by around 4 days overall.
Whilst that's a great improvement it's not exactly the world improving best seller.

[fatnacker] 08/5/2020 08:40

Gotta love the Daily Mail, they're great at saying "experts say" but never tell us exactly who those experts are.